Moderna slips despite Q2 beat amid trial setback (MRNA:NASDAQ)
· seekingalpha.com
Moderna (MRNA) stock dips as the company announces a Phase 3 trial setback for its norovirus vaccine despite better-than-expected Q2 2026 results. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...